ERBB2 and lung carcinoma: T-DM1 with osimertinib is being evaluated in EGFR mutant lung cancer (NCT03784599) and T-DM1 monotherapy is being tested in advanced ErbB2-positive colorectal cancer patients progressing after trastuzumab and lapatinib (NCT03418558).